Enlivex Therapeutics (ENLV) Competitors $1.23 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$1.20 -0.03 (-2.36%) As of 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ENLV vs. TARA, ATOS, HURA, PROC, CCCC, ANIX, MIST, MCRB, HLVX, and JSPRShould you be buying Enlivex Therapeutics stock or one of its competitors? The main competitors of Enlivex Therapeutics include Protara Therapeutics (TARA), Atossa Genetics (ATOS), TuHURA Biosciences (HURA), Procaps Group (PROC), C4 Therapeutics (CCCC), Anixa Biosciences (ANIX), Milestone Pharmaceuticals (MIST), Seres Therapeutics (MCRB), HilleVax (HLVX), and Jasper Therapeutics (JSPR). These companies are all part of the "pharmaceutical products" industry. Enlivex Therapeutics vs. Its Competitors Protara Therapeutics Atossa Genetics TuHURA Biosciences Procaps Group C4 Therapeutics Anixa Biosciences Milestone Pharmaceuticals Seres Therapeutics HilleVax Jasper Therapeutics Protara Therapeutics (NASDAQ:TARA) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, media sentiment, valuation, dividends, earnings, institutional ownership and analyst recommendations. Which has higher earnings & valuation, TARA or ENLV? Enlivex Therapeutics is trading at a lower price-to-earnings ratio than Protara Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProtara TherapeuticsN/AN/A-$44.60M-$1.72-1.83Enlivex TherapeuticsN/AN/A-$15.01M-$0.66-1.86 Do analysts recommend TARA or ENLV? Protara Therapeutics presently has a consensus target price of $20.50, indicating a potential upside of 550.79%. Enlivex Therapeutics has a consensus target price of $10.00, indicating a potential upside of 713.01%. Given Enlivex Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Enlivex Therapeutics is more favorable than Protara Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Protara Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14Enlivex Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 Is TARA or ENLV more profitable? Protara Therapeutics' return on equity of -36.37% beat Enlivex Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Protara TherapeuticsN/A -36.37% -33.29% Enlivex Therapeutics N/A -57.67%-50.52% Does the media refer more to TARA or ENLV? In the previous week, Protara Therapeutics and Protara Therapeutics both had 1 articles in the media. Protara Therapeutics' average media sentiment score of 1.87 equaled Enlivex Therapeutics'average media sentiment score. Company Overall Sentiment Protara Therapeutics Very Positive Enlivex Therapeutics Very Positive Which has more risk and volatility, TARA or ENLV? Protara Therapeutics has a beta of 1.35, indicating that its stock price is 35% more volatile than the S&P 500. Comparatively, Enlivex Therapeutics has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500. Do insiders & institutionals have more ownership in TARA or ENLV? 38.1% of Protara Therapeutics shares are owned by institutional investors. Comparatively, 1.0% of Enlivex Therapeutics shares are owned by institutional investors. 8.4% of Protara Therapeutics shares are owned by company insiders. Comparatively, 12.3% of Enlivex Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. SummaryProtara Therapeutics beats Enlivex Therapeutics on 6 of the 11 factors compared between the two stocks. Get Enlivex Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ENLV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ENLV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ENLV vs. The Competition Export to ExcelMetricEnlivex TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$29.09M$2.42B$5.52B$9.32BDividend YieldN/A1.79%4.25%4.05%P/E Ratio-1.869.1828.1519.68Price / SalesN/A737.05438.33100.29Price / CashN/A160.6835.5357.53Price / Book1.234.698.235.67Net Income-$15.01M$30.99M$3.23B$257.51M7 Day Performance-5.38%0.60%-0.01%0.52%1 Month Performance19.42%7.93%5.61%8.84%1 Year Performance-12.77%-5.48%26.52%14.18% Enlivex Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ENLVEnlivex Therapeutics2.8386 of 5 stars$1.23flat$10.00+713.0%-12.8%$29.09MN/A-1.8670Positive NewsTARAProtara Therapeutics2.0692 of 5 stars$2.80-3.1%$20.50+632.1%+28.2%$111.50MN/A-1.6330Positive NewsATOSAtossa Genetics3.1467 of 5 stars$0.85-0.4%$6.17+629.1%-34.7%$109.68MN/A-4.038Positive NewsHURATuHURA Biosciences1.3698 of 5 stars$2.40-3.2%$12.67+427.8%N/A$108.33MN/A0.00N/APROCProcaps GroupN/A$0.95-40.3%N/A-62.7%$107.18M$409.92M0.004,900Gap DownHigh Trading VolumeCCCCC4 Therapeutics2.9934 of 5 stars$1.52+2.7%$12.00+689.5%-67.5%$105.09M$35.58M-1.03150ANIXAnixa Biosciences2.9076 of 5 stars$3.21-0.6%$9.00+180.4%-0.6%$104.04M$210K-8.455News CoverageMISTMilestone Pharmaceuticals2.7301 of 5 stars$2.17+11.9%$7.00+222.6%-6.6%$103.72M$1M-2.7830Analyst RevisionHigh Trading VolumeMCRBSeres Therapeutics3.4484 of 5 stars$10.85-8.6%$73.67+579.0%-38.4%$103.65M$126.32M-2.36330Positive NewsGap DownHLVXHilleVax2.0763 of 5 stars$2.05-0.5%$3.00+46.3%+21.7%$103.29MN/A-0.9520Positive NewsJSPRJasper Therapeutics3.6761 of 5 stars$3.04-55.1%$48.00+1,478.9%-83.4%$101.70MN/A-0.5820Analyst RevisionHigh Trading Volume Related Companies and Tools Related Companies TARA Competitors ATOS Competitors HURA Competitors PROC Competitors CCCC Competitors ANIX Competitors MIST Competitors MCRB Competitors HLVX Competitors JSPR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ENLV) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredIs this secretive Asian company trying to take over Bitcoin?A mysterious Asian conglomerate is buying billions in Bitcoin — but one legendary trader says that’s the wrong...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enlivex Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enlivex Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ENLV Stock Alerts